CompletedNot Applicable

Antibiotics Use and Carriage of Methicillin-resistant Staphylococci in Community Patients

France571 participantsStarted 2010-03

Plain-language summary

In this prospective, observational, multicentric open study, the investigators will compare the acquisition rates of methicillin-resistant staphylococci (coagulase-negative staphylococci and Staphylococcus aureus) nasal carriage in community patients receiving an ambulatory antibiotic treatment by either a β-lactam (amoxicillin-clavulanate or penicillins M), a macrolide, a synergistin or a fluoroquinolone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

INCLUSION CRITERIA: * Age older than 18 * Prescription by a General Practitioner (investigator) of a β-lactam (amoxicillin-clavulanate or penicillins M), a macrolide, a synergistin or a fluoroquinolone for a minimal expected duration of 5 days (whatever the indication) * Informed consent to the study protocol NON-INCLUSION CRITERIA: * Hospitalization within the previous 6 months * Antibiotherapy within the previous 2 months * Combination antibiotherapy EXCLUSION CRITERIA: * Prescription of a second-line antibiotherapy after inclusion * Withdrawal of informed consent

What they're measuring

Short-term impact of ambulatory use of β-lactams (amoxicillin-clavulanate or penicillins M), macrolides, synergistin or fluoroquinolones on MR-CoNS nasal carriage in community patients

Timeframe: Between 5 days and 15 days

Trial details

NCT IDNCT01489878

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2012-05

View on ClinicalTrials.gov More Methicillin Resistant Staphylococcus Aureus trials